News & Updates

Bimekizumab outperformed risankizumab in the American College of Rheumatology ≥50 percent response criteria (ACR50) among patients with active psoriatic arthritis (PsA) in the phase IIIb BE BOLD trial – the first head-to-head PsA study to demonstrate superiority for a joint-focused primary endpoint. 

Prenatal paracetamol exposure is not associated with an increased risk of attention‑deficit/ hyperactivity disorder (ADHD) or autism spectrum disorder (ASD), according to researchers from the University of Hong Kong (HKU).

Hypofractionated proton therapy achieves an 8-month survival rate of 100 percent, preserves quality of life (QoL), and also lowers radiation exposure to the lungs and heart and reduces toxicity (eg, skin-related reactions) in Chinese patients with breast cancer compared with traditional photon radiotherapy, according to two first-of-its-kind studies in Asia conducted by researchers at the Hong Kong Sanatorium & Hospital (HKSH).

Surrogate indexes calculated from oral glucose tolerance tests (OGTTs) effectively predict the development of type 2 diabetes (T2D), suggests a US study. On the other hand, measures based on fasting insulin are more useful than those that do not measure insulin.

Use of osilodrostat is effective at controlling hypercortisolism in one of three (66.7 percent) patients with adrenal Cushing's syndrome (CS) treated for longer than 4 weeks and in nearly four of five (87.5 percent) individuals treated for more than 12 weeks, a real-world study has shown. It also displays a positive impact on blood pressure and body weight.

In a study presented at ESHRE 2026, a novel, wearable transcutaneous auricular vagus nerve stimulation (taVNS) device alleviates menstrual pain and complications of primary dysmenorrhoea.